← back to search

Simone Filosto

Gilead Sciences (United Kingdom) · GB
Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include CAR-T cell therapy research, Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, and Immunotherapy and Immune Responses.
h-index
21
citations
3,568
works
249
NIH funding
primary concept
Medicine
email

Recent publications

Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma
Nature Medicine 2024cited by 104position: middledoi
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
New England Journal of Medicine 2023cited by 398position: middledoi
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Blood Cancer Discovery 2023cited by 45position: firstdoi
Abstract 5879: Defining the cancer Immunogram using multimodal analysis to guide immunotherapy in diffuse large B cell lymphoma
Cancer Research 2023cited by 0position: middledoi
Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Journal of Clinical Oncology 2022cited by 10position: middledoi
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
New England Journal of Medicine 2021cited by 1,479position: middledoi
Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Blood 2021cited by 21position: middledoi
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer
Nature Medicine 2016cited by 243position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Régis Perbost · Hôpital Laveran3 papers (2022–2024)Adrian Bot · Centre Hospitalier Universitaire de Rennes3 papers (2022–2024)Saran Vardhanabhuti · Gilead Sciences (Australia)3 papers (2022–2024)Jérôme Galon · Inserm3 papers (2022–2024)Rhine R. Shen · Kite (United States)3 papers (2022–2024)Justin Chou · Eureka Therapeutics (United States)3 papers (2022–2024)Frederick L. Locke · Moffitt Cancer Center3 papers (2022–2024) · 2 papers (2022–2024)Justin A. Budka · Indiana University School of Medicine2 papers (2023–2024)Lazaros J. Lekakis · Case Western Reserve University2 papers (2023–2023)Christina To · University of California, Irvine2 papers (2022–2024)Peter Dreger · Heidelberg Engineering (Germany)2 papers (2022–2024)Pier Luigi Zinzani · Marche Polytechnic University2 papers (2022–2024)Wangshu Zhang · Ningbo University2 papers (2022–2024)Brian T. Hill · Cleveland Clinic2 papers (2022–2024)Armando López‐Guillermo · Barcelona Supercomputing Center2 papers (2022–2024)Marco Schupp · Integrated BioTherapeutics (United States)2 papers (2023–2024)Caron A. Jacobson · Harvard University1 papers (2023–2023)Tan Trinh · University of Houston1 papers (2023–2023)Xavier Poiré · Cliniques Universitaires Saint-Luc1 papers (2023–2023)